retatrutide development status eli lilly fda approval is now pharma's top revenue company. It just got for an oral GLP-1, but Wall Street isn't celebrating Retatrutide FDA Approval Status 2026:

Jay Campbell (1:00:52) Just have me back

[DOI] [PMC free article] [PubMed] 4.E

If you are developing an oral, small-molecule GLP-1 pipeline, orforglipron-class intermediates present a more accessible manufacturing challenge

10.1111/bcp.12777 150 MaX.MengJ.JiaM.BiL.ZhouY.WangY.et al (2013)

"however, Lilly is continuing to evaluate body composition and long-term outcomes." Mind Your Gallbladder People who lose large amounts of body fat in short periods of time may also be at greater risk of developing gallstones, says Rozalina McCoy, an endocrinologist at the University of Maryland School of Medicine

Changing the landscape for type 1 diabetes: the first step to prevention